CTK Biotech, Inc.

CTK Biotech, Inc. is a diagnostic biotechnology company specializing in the development and manufacturing of rapid diagnostic tests, aiming to improve healthcare outcomes through quick and reliable testing solutions. CTK Biotech, founded in 1997 in Poway, US, focuses on developing and manufacturing rapid diagnostic tests. The company has not undergone any notable pivots or changes in operations.

Diana Bernal established the company, and it has been operational since, with its management led by CEO Catherine Chen and team members Jason Cranford, Jorge Parra, and Vincent Zhang. In August 2020, SSI Diagnostica A/S, a portfolio company of Adelis Equity Partners, agreed to acquire CTK Biotech, with the financial terms undisclosed. The company has completed one deal to date, with the most recent deal dated August 26, 2020. CTK Biotech specializes in the development and manufacturing of rapid diagnostic tests, notably recognized for their OnSite® product line.

Their core offerings include the OnSite® Syphilis Ab Combo Rapid Test, OnSite® Dengue Ag Rapid Test, and the OnSite® Influenza A/B Ag Rapid Test, which deliver reliable results in 15 minutes or less. These products target critical health concerns, specifically addressing sexually transmitted infections and mosquito-borne diseases, prevalent in various regions worldwide. The tests are utilized by healthcare providers, laboratories, and clinics, bolstering diagnostic capabilities and improving patient outcomes across Europe, Asia, and Latin America. With recent CE marking under the European In Vitro Diagnostic Regulation, CTK Biotech enhances access to essential diagnostics, catering to a broad client base that includes healthcare professionals and institutions seeking rapid and accurate testing solutions.

CTK Biotech generates revenue primarily through the sale of its diagnostic testing products, operating on a business-to-business (B2B) model that involves partnerships with healthcare providers, laboratories, and distributors. Clients typically purchase the OnSite® products either directly or through established distribution channels, ensuring wide accessibility across various healthcare settings. The revenue structure is supported by transactional agreements, where clients order products as needed based on their testing demands, potentially establishing long-term contracts for consistent supply. While specific pricing details for the flagship products are not disclosed, the company's focus on rapid, point-of-care testing solutions positions them competitively within the diagnostic market, appealing to healthcare providers who require efficiency and reliability in their testing processes.

CTK Biotech is strategically positioned for future growth through the introduction of new products designed to enhance their diagnostic capabilities. The company aims to expand into emerging markets and regions, focusing on increasing their presence in Asia and Latin America by 2022. Recent funding, derived from the acquisition deal completed in August 2020, will be utilized to support the development of upcoming products and facilitate market entry strategies, ensuring CTK Biotech remains competitive in the rapidly evolving diagnostic landscape.